BBNX
Beta Bionics, Inc.
Price as of Jul 20, 2026
BBNX earnings
Beta Bionics, Inc. earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 21, 2026 | $-0.53 | $-0.49 | +7.5% | $28M | +2.5% |
| Feb 17, 2026 | $-0.42 | $-0.30 | +28.6% | $32M | +18.5% |
| Oct 28, 2025 | $-0.45 | $-0.33 | +26.7% | $27M | -5.7% |
| Jul 29, 2025 | $-0.51 | $-0.39 | +23.5% | $23M | +6.1% |
| Mar 25, 2025 | $-0.42 | $-1.82 | -333.3% | $20M | +26.6% |
| Dec 31, 2023 | — | $-3.13 | — | $8M | — |
| Sep 30, 2023 | — | $-1.71 | — | $3M | — |
Earnings call summary
Q1 FY2026 · April 21, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Q1 performance exceeded expectations with revenue driven by new patient starts and recurring revenue from pharmacy install base. - Gross margin was strong due to pharmacy install base and lower material costs. - Operating expenses increased, with sales and marketing driven by expanding field sales team, R&D by mint and bi-hormonal projects, and G&A by scaling. - Remediation efforts ongoing for FDA warning letter, including work on complaint handling. - Pipeline updates: Mint patch pump advanced toward 2027 launch, bi-hormonal system initiated phase 2A feasibility trial, Bionic Insights launched in healthcare provider portal, and continued interest in type 2 diabetes indication.
Guidance
- Revised full year 2026 revenue guidance raised to $131 - $136 million from prior $130 - $135 million. - Pharmacy mix guidance raised to 37 - 39% of new patient starts reimbursed through pharmacy from prior 36 - 38%. - Gross margin outlook raised to 57.5% - 59.5% from prior 55.5% - 57.5%. - Operating expenses expected to accelerate growth for remainder of the year due to sales force expansion, marketing investment, and spending on mint and bi-hormonal programs.
Segment performance
In Q1, the company delivered $27.6 million in net sales, growing 57% year over year. Revenue growth was driven by new patient starts and the growing pharmacy install base. Q1 gross margin was 59.5%, expanding 864 basis points year over year. The pharmacy install base generated high margin recurring revenue and crossed a threshold where it became accretive to gross margin. Lower cost of materials for the islet and one-time gross margin tailwinds also contributed. New patient starts declined more than 10% but less than 20% compared to Q4 2025, with a high 30s percentage of new patient starts accessing islet through the pharmacy channel, an increase from prior quarters. Approximately 70% of new patient starts came from people with diabetes using multiple daily injections prior to starting the islet.
Risks & headwinds
- Ongoing need to fully address FDA warning letter concerns, including work in other areas besides complaint handling. - Unpredictability in gross margin due to possible discrete and semi-unpredictable one-time charges in cost of sales. - Potential challenges in managing customer acquisition costs as the market becomes more competitive.
Analyst Q&A
Q: Mike Crackey asked about pharmacy channel new start percentage and Salesforce expansion.
A: Pharmacy channel new start percentage has a B2B sales, long cycle, and guidance acknowledges that. Salesforce expansion has more to happen with most expansion in first half of the year.
Q: David Roman asked about ADA guideline changes, GLP-1s, and OPEX.
A: ADA guideline changes not significantly impacting prescribing patterns. GLP-1s have limited impact on type 1 and insulin-managed type 2. OPEX will grow due to sales force expansion and direct-to-consumer advertising, with customer acquisition costs expected to decrease through building install base and brand.
Q: Frank Takanan asked about gross margin and cash burn.
A: Q1 had one-time gross margin tailwinds, and cash burn in Q1 was higher due to cash bonuses and working capital differences.
Q: John Block asked about sales revenue cadence and gross margin.
A: Not giving quarterly revenue guidance but first half of 2026 expected to have more revenue. Gross margin expected to uptick quarter over quarter from normalized Q1 number.
Q: Richard Newitter asked about pharmacy channel competition and economics.
A: More competitors in pharmacy channel make it more normal, and insulin pumps are non-commoditized limiting downward price pressure.
Q: Jeff Johnson asked about pharmacy rebates and mint timing.
A: Rebates balanced with copay assistance, and mint on track with timeline for 2027 launch.
Q: Jeffrey Cohen asked about cost of materials and bi-hormonal trials.
A: Lower cost of materials due to scale, and bi-hormonal trials updates not to be published.
Q: Matthew Blackman asked about new patient ads and Salesforce expansion.
A: Not commenting on new patient ads quantification, and Salesforce expansion involves both white space filling and replacing in covered areas.
Q: Travis Steed asked about revenue guidance and new patient starts.
A: Revenue guidance can be exceeded by islet confidence, clinical results, and new store sales. Q1 is weakest seasonally with uptick expected in subsequent quarters.
Q: Ryan Schiller asked about competition.
A: No recent impactful changes in competitive environment, focusing on getting word out about differentiated islet system
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-07-29.